Replimune Group Inc

General ticker "REPL" information:

  • Sector: Health Care
  • Industry: Biotechnology
  • Capitalization: $1.0B

Replimune Group Inc follows the US Stock Market performance with the rate: 47.1%.

Estimated limits based on current volatility of 3.7%: low 11.92$, high 12.84$

Factors to consider:

  • Earnings for 3 months up through Q1 are below our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2024-03-31 to 2026-03-31

  • 2024-03-31 to 2025-03-31 estimated range: [5.13$, 12.26$]
  • 2025-03-31 to 2026-03-31 estimated range: [4.63$, 10.85$]

Financial Metrics affecting the REPL estimates:

  • Negative: Non-GAAP EPS, $ of -3.24 <= 0.10
  • Negative: Operating profit margin, % of -100 <= 1.03
  • Negative: Operating cash flow per share per price, % of -24.51 <= 2.35
  • Negative: negative Net income
  • Negative: Industry operating cash flow per share per price (median), % of -24.50 <= 3.85
  • Negative: Inventory ratio change, % of 100 > 1.08

Similar symbols

Short-term REPL quotes

Long-term REPL plot with estimates

Financial data

YTD 2022-03-31 2023-03-31 2024-03-31
Operating Revenue $0.00MM $0.00MM $0.00MM
Operating Expenses $118.31MM $177.08MM $234.77MM
Operating Income $-118.31MM $-177.08MM $-234.77MM
Non-Operating Income $0.28MM $3.08MM $19.39MM
Interest Expense $2.22MM $4.16MM $0.00MM
R&D Expense $79.55MM $126.53MM $174.96MM
Income(Loss) $-118.04MM $-174.00MM $-215.39MM
Taxes $0.00MM $0.29MM $0.41MM
Profit(Loss) $-118.04MM $-174.28MM $-215.79MM
Stockholders Equity $411.23MM $555.29MM $374.51MM
Assets $461.19MM $646.59MM $487.72MM
Operating Cash Flow $-82.18MM $-128.05MM $-185.47MM
Capital expenditure $2.34MM $2.27MM $5.66MM
Investing Cash Flow $-1.81MM $-142.50MM $97.20MM
Financing Cash Flow $6.60MM $311.30MM $16.28MM
Earnings Per Share* $-2.26 $-2.99 $-3.24

* EPS are Split Adjusted, recent splits may be reflected with a delay.